A therapeutic breast cancer vaccine is one step closer as a result of work conducted at the Austin Research Institute, Melbourne, Australia. Last July, Ms Vasso Apostolopoulos, a PhD student at the institute, started work on a breast cancer vaccine based on the mucin MUC1 - a large molecule comprising a protein core which occurs in breast cancer and triggers a very weak immune response. Her aim is to use this molecule to enhance the natural immune response to breast cancer. Currently, 2 synthetic peptides have been made and tested bothin vitroandin vivo, producing promising results. Ms Apostolopoulos spoke withInpharmaabout the project to date.